Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) has been assigned a consensus recommendation of “Reduce” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $28.00.
A number of brokerages recently weighed in on FMS. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Zacks Research upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Wall Street Zen lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Sanford C. Bernstein assumed coverage on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Thursday. They issued a “market perform” rating on the stock. Finally, Citigroup reissued a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, April 24th.
View Our Latest Stock Analysis on FMS
Fresenius Medical Care AG & Co. KGaA Stock Performance
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.05 earnings per share (EPS) for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%.The firm had revenue of $5.34 billion during the quarter. As a group, analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current year.
Fresenius Medical Care AG & Co. KGaA Increases Dividend
The company also recently disclosed an annual dividend, which was paid on Monday, June 8th. Shareholders of record on Friday, May 22nd were issued a dividend of $0.8716 per share. This represents a yield of 402.0%. This is a positive change from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. The ex-dividend date of this dividend was Friday, May 22nd. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio is currently 32.11%.
Institutional Trading of Fresenius Medical Care AG & Co. KGaA
Several hedge funds have recently made changes to their positions in FMS. CIBC Private Wealth Group LLC lifted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after buying an additional 1,103 shares during the last quarter. Arax Advisory Partners increased its holdings in Fresenius Medical Care AG & Co. KGaA by 121.6% in the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after buying an additional 885 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Fresenius Medical Care AG & Co. KGaA during the fourth quarter valued at approximately $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Fresenius Medical Care AG & Co. KGaA during the fourth quarter valued at approximately $58,000. Finally, Group One Trading LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the third quarter valued at approximately $74,000. 8.37% of the stock is currently owned by institutional investors.
Fresenius Medical Care AG & Co. KGaA Company Profile
Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.
In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.
Featured Stories
- Five stocks we like better than Fresenius Medical Care AG & Co. KGaA
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
